Fractyl Health, Inc. (GUTS)
| Previous Close | 3.5000 |
| Open | 3.4400 |
| Bid | 3.4700 x 200 |
| Ask | 3.5600 x 100 |
| Day's Range | 3.3358 - 3.7000 |
| 52 Week Range | 1.7400 - 14.5000 |
| Volume | |
| Avg. Volume | 290,871 |
| Market Cap | 167.745M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.50 |
Simply Wall St.Fractyl Health Second Quarter 2024 Earnings: US$0.36 loss per share (vs US$14.56 loss in 2Q 2023)
Fractyl Health ( NASDAQ:GUTS ) Second Quarter 2024 Results Key Financial Results Net loss: US$17.2m (loss narrowed by...
GlobeNewswireFractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates
Updated clinical results from German Real-World Registry demonstrate potential for Revita? to meaningfully sustain weight loss and lower blood sugar for at least one-year post-treatment in a real-world setting Granted U.S. FDA Breakthrough Device designation for Revita in weight maintenance after discontinuation of GLP-1 based drugs REMAIN-1 pivotal study for Revita in weight maintenance now initiated with anticipated data readouts beginning in Q4 2024 REVITALIZE-1 on-track to report topline dat
Medical Device NetworkRising diabetes rates spur growth in weight management solutions
Diabetes is a chronic health condition that affects how the body turns food into energy. When a person eats, the body breaks down most food into sugar (glucose) and releases it into the bloodstream. When blood sugar goes up, it signals the pancreas to release insulin. Insulin acts as a key to let the blood…
